Clinical Trial: The Study Of Andamertinib Plus Anlotinib In Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

U.S., Aug. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07780578) titled 'The Study Of Andamertinib Plus Anlotinib In Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer' on Aug. 19.

Brief Summary: This study is a single arm study to access the anti-tumor efficacy and safety of Andamertinib plus Anlotinib in patients with locally advanced or metastatic non-small cell lung cancer previously treated with third-generation EGFR-TKI.

Study Start Date: Sept. 30

Study Type: INTERVENTIONAL

Condition: Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line

Intervention: DRUG: Andamertinib + Anlotinib

Andamertinib: 160mg, QD, Q3W Anlotinib: 12mg/10mg, QD, d1-d14, Q3...